Dallas-based AI-driven wound care company Spectral AI, Inc. announced that the company’s board of directors has appointed Vincent S. Capone as chief executive officer, effective February 9, 2026.

Capone, who has been serving as the company’s CFO and general counsel, takes on the CEO role as Spectral AI prepares for the commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device the DeepView System, the company said.

“Vince brings a unique set of leadership skills to his new role, combining a background in law, accounting, finance and operations management supported by a strong vision for the company’s future,” Dr. J. Michael DiMaio, chairman of the board of Spectral AI, said in a statement.

Spectral MD’s DeepView device [Photo: Spectral AI]

“He has a strong passion for our mission to provide clinicians with a novel technology that re-imagines the current standard of care in burn wound assessment,” DiMaio added. “Vince has played an integral role working with me in leading Spectral AI to this point in our development, and he has earned the respect of our Board, leadership, team members, and partners. His appointment as CEO will help to ensure the evolution of our strategic direction with me as Executive Chairman.”

Capone has served as Spectral AI’s CFO since February 2024 and as general counsel since March 2022. He has been a member of the Office of the Chairman since October 2024 which, under the leadership of DiMaio, has been responsible for day-to-day operational responsibilities and support of the clinical development and commercialization of the DeepView System.

Capone started his career at KPMG LLP before practicing corporate and securities law as a partner with Reed Smith LLP. Prior to joining Spectral AI, he was president of a New York-based private equity fund investing in global life sciences and technology companies.

“I’m honored to assume the role of CEO as the company evolves towards commercialization,” Capone said. “I’m also thankful to work alongside a talented team who drive our success every day.”

“Our FDA submission of the DeepView System in June 2025 marked a major milestone for Spectral AI and a critical step forward to providing this innovative and potentially transformative technology,” Capone added. “We’re excited to deliver DeepView to the broader healthcare market and advance burn wound care in the U.S. and around the world.”

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.